Oral Agents for Multiple Sclerosis
{"Image DocumentName": "Oral Agents for Multiple Sclerosis", "Image ImageDescription": "Mechanism of Action. Status. Expected Dosing. Dalfampridine. Potassium channel blocker. Approved for use by the FDA mg twice daily. Laquinimod. Immunomdulator. Granted fast-track review by FDA. 0.6 mg daily. Cladribine. Purine nucleoside analogue prodrug. FDA issued a refuse-to-file letter for the New Drug Application due to reports of patients developing solid malignancies. 1 (0.2) Fingolimod. Partial sphingosine 1-phosphate-receptor agonist. Approved for use by FDA. 0.5 mg daily. FDA data accessed 10/14/10.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}